Abstract Objective To study the clinical effect of mouse nerve growth factor (mNGF) in the treatment of children with global developmental delay (GDD). Methods A prospective clinical trial was conducted in 60 children with GDD who were treated in the First Affiliated Hospital of Anhui Medical University between July 2016 and July 2017. These children were randomly divided into two groups: conventional rehabilitation treatment and mNGF treatment group (n=30 each). The children in the conventional rehabilitation treatment group were given neurodevelopmental therapy, and those in the mNGF treatment group were given mNGF treatment in addition to the treatment in the control group. The evaluation results of the Gesell Developmental Scale were compared between the two groups before and after treatment. Results Before treatment and after 1.5 months of treatment, there was no significant difference in the developmental quotient (DQ) of each functional area of the Gesell Developmental Scale between the mNGF treatment and conventional rehabilitation treatment groups (P>0.05). After 3 months of treatment, the mNGF treatment group had significantly higher DQs of gross motor, fine motor, and personal-social interaction than the conventional rehabilitation treatment group (P?0.05). The incidence rate of transient injection site pain after injection of mNGF was 7% (2/30), and there was no epilepsy or other serious adverse reactions. Conclusions In children with GDD, routine rehabilitation training combined with mNGF therapy can significantly improve their cognitive, motor, and social abilities.
YUAN Jin-Jing,WU De,WANG Wen-Wen et al. A prospective randomized controlled study on mouse nerve growth factor in the treatment of global developmental delay in children[J]. CJCP, 2021, 23(8): 786-790.
YUAN Jin-Jing,WU De,WANG Wen-Wen et al. A prospective randomized controlled study on mouse nerve growth factor in the treatment of global developmental delay in children[J]. CJCP, 2021, 23(8): 786-790.
Mithyantha R, Kneen R, McCann E, et al. Current evidence-based recommendations on investigating children with global developmental delay[J]. Arch Dis Child, 2017, 102(11): 1071-1076. DOI: 10.1136/archdischild-2016-311271. PMID: 29054862. PMCID: PMC5738593.
Jeong JW, Sundaram S, Behen ME, et al. Differentiation of speech delay and global developmental delay in children using DTI tractography-based connectome[J]. AJNR Am J Neuroradiol, 2016, 37(6): 1170-1177. DOI: 10.3174/ajnr.A4662. PMID: 26797142. PMCID: PMC4907870.
Dornelas LF, Duarte NM, Morales NM, et al. Functional outcome of school children with history of global developmental delay[J]. J Child Neurol, 2016, 31(8): 1041-1051. DOI: 10.1177/0883073816636224. PMID: 26936059.
Bélanger SA, Caron J. Evaluation of the child with global developmental delay and intellectual disability[J]. Paediatr Child Health, 2018, 23(6): 403-419. DOI: 10.1093/pch/pxy093. PMID: 30919832. PMCID: PMC6234423.
Choo YY, Agarwal P, How CH, et al. Developmental delay: identification and management at primary care level[J]. Singapore Med J, 2019, 60(3): 119-123. DOI: 10.11622/smedj.2019025. PMID: 30997518. PMCID: PMC6441684.
Sone Y, Takatori S, Ochi E, et al. Nerve growth factor facilitates the innervation of perivascular nerves in tumor-derived neovasculature in the mouse cornea[J]. Pharmacology, 2017, 99(1-2): 57-66. DOI: 10.1159/000450582. PMID: 27694752.
Zhao M, Li XY, Xu CY, et al. Efficacy and safety of nerve growth factor for the treatment of neurological diseases: a meta-analysis of 64 randomized controlled trials involving 6,297 patients[J]. Neural Regen Res, 2015, 10(5): 819-828. DOI: 10.4103/1673-5374.156989. PMID: 26109961. PMCID: PMC4468778.
Yoshida T, Hiraiwa A, Ibuki K, et al. Neurodevelopmental outcomes at 3 years for infants with congenital heart disease and very-low birthweight[J]. Pediatr Int, 2020, 62(7): 797-803. DOI: 10.1111/ped.14160. PMID: 31957091.
Li YH, Anderson LA, Ginns EI, et al. Cost effectiveness of karyotyping, chromosomal microarray analysis, and targeted next-generation sequencing of patients with unexplained global developmental delay or intellectual disability[J]. Mol Diagn Ther, 2018, 22(1): 129-138. DOI: 10.1007/s40291-017-0309-5. PMID: 29209992.
Alamri A, Aljadhai YI, Alrashed A, et al. Identifying clinical clues in children with global developmental delay/intellectual disability with abnormal brain magnetic resonance imaging (MRI)[J]. J Child Neurol, 2021, 36(6): 432-439. DOI: 10.1177/0883073820977330. PMID: 33295251.
Rocco ML, Soligo M, Manni L, et al. Nerve growth factor: early studies and recent clinical trials[J]. Curr Neuropharmacol, 2018, 16(10): 1455-1465. DOI: 10.2174/1570159X16666180412092859. PMID: 29651949. PMCID: PMC6295934.
Antonov SA, Manuilova ES, Dolotov OV, et al. Effect of nerve growth factor on neural differentiation of mouse embryonic stem cells[J]. Bull Exp Biol Med, 2017, 162(5): 679-683. DOI: 10.1007/s10517-017-3686-1. PMID: 28364186.
Paoletti F, Malerba F, Ercole BB, et al. A comparative analysis of the structural, functional and biological differences between mouse and human nerve growth factor[J]. Biochim Biophys Acta, 2015, 1854(3): 187-197. DOI: 10.1016/j.bbapap.2014.12.005. PMID: 25496838.
Wang QZ, Zhao HC, Zheng TH, et al. Otoprotective effects of mouse nerve growth factor in DBA/2J mice with early-onset progressive hearing loss[J]. J Neurosci Res, 2017, 95(10): 1937-1950. DOI: 10.1002/jnr.24056. PMID: 28345280. PMCID: PMC5561496.
Yin XJ, Dong L, Wei W, et al. Effect of mouse nerve growth factor on the expression of glial fibrillary acidic protein in hippocampus of neonatal rats with hypoxic-ischemic brain damage[J]. Exp Ther Med, 2013, 5(2): 419-422. DOI: 10.3892/etm.2012.827. PMID: 23408790. PMCID: PMC3570183.
Tuszynski MH, Yang JH, Barba D, et al. Nerve growth factor gene therapy: activation of neuronal responses in alzheimer disease[J]. JAMA Neurol, 2015, 72(10): 1139-1147. DOI: 10.1001/jamaneurol.2015.1807. PMID: 26302439. PMCID: PMC4944824.
Rafii MS, Tuszynski MH, Thomas RG, et al. Adeno-associated viral vector (serotype 2)-nerve growth factor for patients with Alzheimer disease: a randomized clinical trial[J]. JAMA Neurol, 2018, 75(7): 834-841. DOI: 10.1001/jamaneurol.2018.0233. PMID: 29582053. PMCID: PMC5885277.
Acosta CM, Cortes C, MacPhee H, et al. Exploring the role of nerve growth factor in multiple sclerosis: implications in myelin repair[J]. CNS Neurol Disord Drug Targets, 2013, 12(8): 1242-1256. DOI: 10.2174/18715273113129990087. PMID: 23844684.
